Lab Grown Blood for Transfusions: How Close Are We?
Red blood cells grown from stem cells have already gone into people, in teaspoon doses. Here is what the RESTORE trial is testing, why a full bag is so hard to make, and why donors still matter.
Manufacturing blood is not science fiction anymore. Scientists can grow red blood cells from human stem cells in a lab, and they have already put them into people.[1][2] But this is not a replacement for donated blood. It has reached an early human trial, not the hospital shelf. The question now is not whether it can be done. It is whether it can be done safely, reliably and at a price a health system can pay.
What the RESTORE trial is testing
In November 2022 a British team announced the first clinical trial in which lab grown red cells were transfused into another person. It is led by NHS Blood and Transplant and the University of Bristol, with Cambridge and London hospital partners. The trial is called RESTORE, short for Recovery and Survival of Stem Cell Originated Red Cells.[1][2]
Researchers take blood from donors, pull out the stem cells that make blood, and grow them into red cells. Each healthy volunteer gets two mini transfusions at least four months apart, one of lab grown cells and one of ordinary donated cells, in random order. The dose is about 5 to 10 mL, one or two teaspoons. The plan was at least ten volunteers.[2] It is a phase 1 trial, which mainly checks safety. The hypothesis is simple: fresh lab made cells should last longer in the body than donated cells, which are a mix of young and old.[1]
Who could gain first? People who need transfusions again and again, such as some people with sickle cell disease or rare blood types. Their immune systems can react to small differences in donor blood. Lab grown cells could one day be matched closely, and longer lasting cells could mean fewer transfusions.[2] The trial has not shown that yet.
In February 2026 the last batch of cells for RESTORE was made at NHS Blood and Transplant's Filton unit and given to volunteers. Results are expected in late 2026 or early 2027.[3]
Why a full bag is so hard
One unit of blood holds about two trillion red cells.[4] Going from a teaspoon to a bag is not a small step. The cells have to mature properly, drop their nucleus, carry working {W("hemoglobin","https://en.wikipedia.org/wiki/Hemoglobin")} and show the right {W("blood group","https://en.wikipedia.org/wiki/Blood_type")} markers. Labs are trying bigger culture systems and {W("bioreactors","https://en.wikipedia.org/wiki/Bioreactor")}, machines that grow cells under tight control, but the review authors say bioreactor costs make clinical quantities unlikely any time soon.[4]
Then there is cost. A 2024 review put a donated unit at about $200 to $300, and estimated the same number of lab made cells at $1,000 to $15,000.[4] That is an estimate, not a price on a menu, and methods may get cheaper. The money goes to growth media, equipment, many batches and the testing needed to prove each batch is safe.
Donors are still the supply
The American Red Cross says flatly that blood and platelets cannot be manufactured and can only come from volunteer donors. About 3 percent of age eligible people give blood each year. Red cells must be used within 42 days, and the United States needs about 29,000 units of red cells every day.[5] That is why the supply has to keep flowing, not arrive in a few big drives.
Britain has the same problem. In July 2024 the NHS blood service called an amber alert. It said three donations are needed every minute, blood has a shelf life of 35 days, and O negative stocks had fallen to 1.6 days. O negative matters most in emergencies, when there is no time to test a patient's type.[6]
What about artificial blood?
Lab grown cells are not the only idea. For decades companies have tried artificial blood, mostly hemoglobin based oxygen carriers, fluids that carry oxygen without whole red cells. A March 2026 review found that big clinical trials kept showing more harmful side effects or missed their goals, and that no hemoglobin based oxygen carrier has FDA approval.[7] They are still research, not a substitute for a transfusion.
So how close are we? A real line has been crossed: lab grown red cells have gone into people, and the trial's last batch is done. But the doses are teaspoons in healthy volunteers. Next come the results, then proof the cells survive as hoped, then a way to make trillions of them at a price that makes sense.[3][4] For now, the blood in the hospital fridge comes from a person who rolled up a sleeve. If lab blood arrives, it will likely help people with rare types and complex needs first, long before it is routine.[2]
Sources
- NHS Blood and Transplant, RESTORE (Recovery and survival of stem cell originated red cells), trial page (single centre, randomised, controlled phase I cross over trial in healthy volunteers; mini dose of red cells grown from CD34+ stem cells compared with standard donated red cells; closed to recruitment)
- University of Bristol, "First ever clinical trial of laboratory grown red blood cells being transfused into another person," November 7, 2022 (5 to 10 mL doses, at least ten participants, two mini transfusions at least four months apart; partners; sickle cell and rare blood types)
- NIHR BioResource, "Final batch of red blood cells produced in RESTORE," February 11, 2026 (made at NHSBT's Filton Advanced Therapies Unit; results expected late 2026 or early 2027)
- Hassan and Rajput, "Blood pharming: exploring the progress and hurdles in producing in vitro red blood cells for therapeutic applications," Frontiers in Hematology, March 2024 (about 2 trillion red cells per unit; about US$200 to 300 per donated unit; manufactured cells estimated at US$1,000 to 15,000 for the same number; bioreactor costs)
- American Red Cross, "Blood Needs and Blood Supply" (blood and platelets cannot be manufactured; about 3 percent of age eligible people donate yearly; red cells used within 42 days or less; about 29,000 units of red cells needed every day in the U.S.)
- NHS Blood and Transplant, "NHS calls national blood shortage amber alert," July 25, 2024 (three donations needed every minute; blood has a shelf life of 35 days; O negative stocks at 1.6 days)
- Abdelghany, Amdahl and Xu, "Artificial Oxygen Carriers: Lessons From Hemoglobin Based Oxygen Carrier Clinical Trials and Current Development Efforts," Shock 65(3), March 2026, pages 374 to 389 (abstract: large trials showed more adverse events or missed endpoints; no HBOC has FDA approval)
Inspired by Happy. Prepared by ChatGPT (self reported GPT 6, version unconfirmed). Reviewed and edited by Claude.
Revision history (R0 current)
| Rev | Date | What changed | Page |
|---|---|---|---|
| D1 | Nov 22, 2026, 4:04:06 AM CST (saved on arrival; chat message 4:03 am, minute only) | What ChatGPT returned, unedited. Prompt handed out Nov 22, 3:50:25 AM CST (queue batch of five). About 13 minutes round trip. | view |
| R0 | Nov 22, 2026, 4:34:18 AM CST (reviewed and posted) | First publish, reviewed and edited by Claude (Opus). All seven sources opened (the PubMed page through the authors' university listing). Fixed the 1.5 million units "each year," the 35 day figure and the 3 percent wording to match the sources; added dose size and volunteer count; cut an unsourced perfluorocarbon line. | view |